Welcome to our dedicated page for Clover Health Investments SEC filings (Ticker: CLOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Clover Health Investments, Corp. (Nasdaq: CLOV) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures as a publicly traded Medicare Advantage and healthcare technology issuer. Clover Health files reports with the U.S. Securities and Exchange Commission that describe its Medicare Advantage insurance operations, technology platform, financial performance, risk factors, and governance.
Investors can review current reports on Form 8-K, where Clover Health announces material events such as quarterly financial results, CMS Star Ratings for its Medicare Advantage PPO and HMO plans, and board or governance changes. Some 8-K filings also reference supplemental written responses to shareholder questions, offering additional context on strategy, cohort economics, and the role of Clover Assistant and Counterpart Health in the business.
In addition to 8-Ks, Clover Health’s annual reports on Form 10-K and quarterly reports on Form 10-Q (when available in the feed) typically provide detailed discussions of its Insurance segment, Medicare Advantage membership trends, non-GAAP measures such as Adjusted EBITDA and Insurance Benefits Expense Ratio, and regulatory considerations related to Medicare, CMS Star Ratings, and value-based care arrangements.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand how items such as Star Rating changes, CMS rate updates, or shifts in membership mix may affect Clover Health’s reported results. Users can also track insider transaction reports on Form 4 when they appear, to monitor equity transactions by directors and officers.
Filings are updated in near real time from the SEC’s EDGAR system, allowing investors, analysts, and other stakeholders to follow Clover Health’s evolving disclosures on Medicare Advantage performance, technology initiatives through Clover Assistant and Counterpart Health, and corporate governance developments.
Clover Health Investments executive Jamie L. Reynoso, CEO, Medicare Advantage, had 6,197 shares of Class A Common Stock withheld on April 3, 2026 to cover tax obligations. The withholding related to the vesting of 6.25% of restricted stock units granted on January 3, 2023.
After this tax-withholding disposition, Reynoso directly holds 2,869,922 shares of Class A Common Stock. The remaining RSUs from the 2023 grant will vest in equal quarterly installments through January 3, 2027, subject to Reynoso’s continued service on each vesting date.
Priest Brady Patrick reported acquisition or exercise transactions in this Form 4 filing.
Clover Health Investments insider Brady Patrick Priest, CEO of Clover Care Services, received an award of 191,261 shares of Class A Common Stock in the form of time-based restricted stock units. These RSUs were granted at no cash purchase price as part of his equity compensation.
After this award, Priest directly holds 2,189,845 shares of Class A Common Stock. Twenty-five percent of the RSUs will vest on the first anniversary of April 1, 2026, and the remaining units will vest in twelve equal quarterly installments, becoming fully vested on April 1, 2030, assuming his continued service.
Reynoso Jamie L. reported acquisition or exercise transactions in this Form 4 filing.
Clover Health Investments reported that Jamie L. Reynoso, CEO of Medicare Advantage, received a grant of 159,384 shares of Class A common stock in the form of time-based restricted stock units. These RSUs were awarded at no cash cost per share as equity compensation.
According to the grant terms, 25% of the RSUs will vest on the first anniversary of April 1, 2026. The remaining units will vest in twelve equal quarterly installments starting three months after that first anniversary, so that all RSUs are fully vested by April 1, 2030, subject to continued service. Following this award, Reynoso directly holds 2,876,119 shares of Class A common stock.
Clover Health Investments Chief Executive Officer Andrew Toy reported equity compensation changes involving Class A Common Stock. He received a grant of 956,307 shares underlying time-based restricted stock units, with 25% vesting on the first anniversary of April 1, 2026 and the remainder vesting in 12 equal quarterly installments until April 1, 2030, subject to continued service. On the same date, 309,558 shares were automatically withheld at $1.76 per share to cover tax obligations from the vesting of earlier RSUs granted January 1, 2023. After these transactions, he directly holds 10,069,770 shares of Class A Common Stock.
Wai Conrad reported acquisition or exercise transactions in this Form 4 filing.
Clover Health Investments reported that executive Wai Conrad, CEO of Counterpart Health, received a grant of 267,766 shares of Class A common stock in the form of time-based restricted stock units. The award was granted at $0.00 per share, reflecting a compensation grant rather than a market purchase.
According to the vesting schedule, 25% of these RSUs will vest on the first anniversary of April 1, 2026, with the remaining units vesting in twelve equal quarterly installments beginning three months after that first anniversary, so that all RSUs are fully vested on April 1, 2030, subject to Mr. Conrad’s continued service. Following this grant, he holds 1,193,377 shares directly, and a family trust, for which he is a co-trustee, holds 1,610,482 shares indirectly.
Soares Karen reported acquisition or exercise transactions in this Form 4 filing.
Clover Health Investments Chief Legal Officer Karen Soares received a grant of 382,522 shares of Class A common stock in the form of time-based restricted stock units. These RSUs were awarded at no cash cost and increase her direct ownership to 1,582,583 shares after the grant.
Twenty-five percent of the RSUs will vest on the first anniversary of April 1, 2026. The remaining units will then vest in twelve equal quarterly installments beginning three months after that first anniversary, with all RSUs fully vested on April 1, 2030, assuming she continues in service through each vesting date.
Clover Health Investments announced a planned transition in its finance leadership. Chief Financial Officer Peter Kuipers has stepped down from his roles as CFO, principal financial officer, and principal accounting officer, while remaining in an advisory capacity through April 24, 2026 to support the handoff.
The board appointed Clay Thornton, currently CFO of Clover’s insurance plan, as Interim Chief Financial Officer and principal financial officer, and named Joseph (Joe) Oldakowski as principal accounting officer. The company states that Kuipers’ departure does not reflect any disagreement on operations, policies, or practices, and it reiterates its most recently issued financial guidance for full year 2026.
Clover Health Investments Corp received an amended Schedule 13G/A from The Vanguard Group reporting that Vanguard beneficially owns 0 shares of Clover Health common stock, representing 0% of the class.
The filing notes an internal realignment of Vanguard on January 12, 2026 and states certain subsidiaries will report separately in reliance on SEC Release No. 34-39538. The form is signed on March 26, 2026.
Clover Health Investments executive Jamie L. Reynoso, CEO, Medicare Advantage, sold 5,833 shares of Class A common stock in an open-market transaction at a weighted average price of $1.91 per share. The shares were sold in multiple trades between $1.87 and $1.96 per share pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2025. After this sale, Reynoso directly holds 2,716,735 Class A shares.
Morgan Stanley Smith Barney LLC submitted a Form 144 reporting the proposed sale of 5,833 Restricted Stock Units on 03/14/2026. The filing also discloses prior 10b5-1 sales by Jamie Reynoso: 4,597 shares on 01/20/2026 and 2,102 shares on 01/07/2026, with reported dollar amounts of 11,871.75 and 5,319.32, respectively.